CRIS_OUT_1 [2025-04-28 19:01:31 -0400] 4975 Bytes | 1438 tokens | Cum: 1438 tkns (17.97% of 8k)
==========================================================================

We're scouting for winners today. Its 7:01 PM on Mon Apr 28, 2025 and I'm looking at Curis (CRIS) up to $1.92 from $1.63

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Curis (CRIS)
IPO: 2000-08-01 (24 Years Ago)
Market Cap: $13,600,925
Shares Outstanding: 10,460,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Here’s a list of headlines for Curis:

Apr-12-25 11:00AM - Goldman Sachs, J&J, To Report Earnings As Investors Watch Out For Retail Sales Data
Apr-02-25 04:05PM - Curis to Present at Upcoming Healthcare Conference in April
Apr-01-25 03:01AM - Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ...
Apr-01-25 03:01AM 01:42AM - Q4 2024 Curis Inc Earnings Call
Mar-31-25 09:59AM - Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript
Mar-31-25 09:59AM 08:16AM - Curis: Q4 Earnings Snapshot
Mar-31-25 09:59AM 08:00AM - Curis Provides Fourth Quarter 2024 Business Update
Mar-28-25 04:07PM - Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
Dec-10-24 08:00AM - Curis Announces Additional Data from TakeAim Leukemia Study
Nov-15-24 02:37AM - Q3 2024 Curis Inc Earnings Call
Nov-15-24 02:37AM 02:07AM - Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...
Nov-14-24 09:10AM - Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
Nov-14-24 09:10AM 08:09AM - Curis: Q3 Earnings Snapshot
Nov-14-24 09:10AM 08:00AM - Curis Provides Third Quarter 2024 Business Update
Nov-13-24 07:31AM - Curis Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of Earnings
Nov-07-24 08:00AM - Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
Nov-02-24 11:20AM - Curis price target lowered to $20 from $26 at H.C. Wainwright
Oct-29-24 06:04AM - Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
Oct-09-24 03:42PM - Curis Inc (CRIS) Q2 2024 Earnings Call Highlights: Promising Clinical Progress Amid Financial ...
Sep-23-24 08:30AM - Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer
Sep-17-24 07:30AM - Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference
Sep-04-24 08:00AM - Curis to Present at Upcoming Healthcare Conferences in September

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-07-11T10:09:50Z - VISTA Inhibitor Clinical Trials Drug Approval Insight - GlobeNewswire
B2 - 2024-04-12T12:34:00Z - Top 3 Health Care Stocks That May Collapse In Q2
B3 - 2024-04-05T12:43:00Z - Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
B4 - 2024-02-09T13:11:00Z - CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday
B5 - 2024-01-24T18:05:27Z - Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B6 - 2023-11-17T18:01:38Z - Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Curis (CRIS).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

CRIS_OUT_3 [2025-04-28 19:01:32 -0400] 709 Bytes | 193 tokens | Cum: 1633 tkns (20.41% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2251188/strength-seen-in-curis-cris-can-its-195-jump-turn-into-more-strengthCuris (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CRIS_OUT_5 [2025-04-28 19:01:33 -0400] 894 Bytes | 259 tokens | Cum: 1894 tkns (23.67% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-14T21:06:19Z - 12 Health Care Stocks Moving In Monday's After-Market Session - BioSig Technologies (NASDAQ:BSGM), B...
A2 - 2025-04-09T15:06:08Z - Curis stock plunges to 52-week low at $1.1 amid sharp decline By Investing.com...
A3 - 2025-04-02T20:05:00Z - Curis to Present at Upcoming Healthcare Conference in April...
A4 - 2025-04-02T20:05:00Z - Curis to Present at Upcoming Healthcare Conference in April...
A5 - 2025-04-02T20:05:00Z - Curis to Present at Upcoming Healthcare Conference in April...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CRIS_OUT_7 [2025-04-28 19:01:34 -0400] 1181 Bytes | 353 tokens | Cum: 2249 tkns (28.11% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Monday's After-Market Session - BioSig Technologies (NASDAQ:BSGM), BioAtla (NASDAQ:BCAB)**Date: 2025-04-14Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44802599/12-health-care-stocks-moving-in-mondays-after-market-sessionGainers Precision Optics Corp POCI stock rose 21.4% to $4.7 during Monday's after-market session. The company's market cap stands at $35.8 million. Healthcare Triangle HCTI stock increased by 15.01% to $0.25. The market value of their outstanding shares is at $11.0 million. BioSig Technologies BSGM shares rose 9.52% to $0.69. The company's market cap stands at $16.4 million. Venus Concept VERO shares moved upwards by 8.26% to $4.06. The market value of their outstanding shares is at $2.6 million. BioAtla BCAB shares moved upwards by 7.83% to $0.34. The comp

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CRIS_OUT_9 [2025-04-28 19:01:35 -0400] 1181 Bytes | 355 tokens | Cum: 2606 tkns (32.57% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): any's market cap stands at $19.8 million. NanoVibronix NAOV stock increased by 7.61% to $8.34. The market value of their outstanding shares is at $6.3 million. Losers Geovax Labs GOVX shares decreased by 29.9% to $0.75 during Monday's after-market session. The market value of their outstanding shares is at $7.0 million. Krystal Biotech KRYS stock fell 16.07% to $141.77. The company's market cap stands at $4.0 billion. Seres Therapeutics MCRB stock declined by 13.67% to $0.56. The company's market cap stands at $98.4 million. Minerva Neurosciences NERV stock declined by 12.11% to $1.38. The market value of their outstanding shares is at $9.6 million. cbdMD YCBD stock decreased by 10.42% to $0.21. The company's market cap stands at $1.3 million. Curis CRIS stock decreased by 9.31% to $1.17. The market value of their outstanding shares is at $12.2 million. See Also: www.benzinga.com/money/b

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CRIS_OUT_11 [2025-04-28 19:01:35 -0400] 1057 Bytes | 352 tokens | Cum: 2960 tkns (37.00% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): est-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCABBioAtla Inc$0.3000-0.89%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum1.36Growth-Quality-Value84.29Price TrendShortMediumLongOverviewBSGMBioSig Technologies Inc$0.690018.9%CRISCuris Inc$1.17-%GOVXGeovax Labs Inc$0.8900-12.8%HCTIHealthcare Triangle Inc$0.255015.0%KRYSKrystal Biotech Inc$133.74-18.9%MCRBSeres Therapeutics Inc$0.5800-1.78%NAOVNanoVibronix Inc$8.3423.2%NERVMinerva Neurosciences Inc$1.38-4.83%POCIPrecision Optics Corp Inc$4.043.12%VEROVenus Concept Inc$4.07-5.57%YCBDcbdMD Inc$0.2150-1.78%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CRIS_OUT_13 [2025-04-28 19:01:37 -0400] 1069 Bytes | 280 tokens | Cum: 3242 tkns (40.52% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion of our financial condition and results of operations should be read in conjunction with the Cons Fin Stmnts and the related notes appearing e...

S2 - 2025-03-31 8-K Item 2.02. Results of Oper and Fin Cond.

On March 31, 2025, Curis, Inc. announced its financial results for the three- and twelve-month periods ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished a...

S3 - 2025-03-28 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Securities Purchase Agrmt

On March 28, 2025, Curis, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agrmt) with certain institutional investors (the Purchasers), pursuant to which the ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CRIS_OUT_15 [2025-04-28 19:01:37 -0400] 1181 Bytes | 251 tokens | Cum: 3495 tkns (43.69% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with the Consolidated Financial Statements and the related notes appearing elsewhere in this Annual Report. This discussion contains forward-looking statements, based on current expectations and related to future events and our future financial performance, that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many important factors, including those set forth under Part I, Item 1A, Risk Factors and elsewhere in this Annual Report. As used throughout this Annual Report, the terms the Company, we, us, and our refer to the business of Curis, Inc. and its wholly owned subsidiaries, except wh

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CRIS_OUT_17 [2025-04-28 19:01:38 -0400] 1181 Bytes | 285 tokens | Cum: 3782 tkns (47.27% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ere the context otherwise requires, and the term Curis refers to Curis, Inc.

Overview

Emavusertib

We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4. IRAK4 plays an essential role in the toll-like receptor, or TLR, and interleukin-1 receptor, or IL-1R, signaling pathways, which are frequently dysregulated in patients with cancer. TLRs and the IL-1R family signal through the adaptor protein Myeloid Differentiation Primary Response Protein 88, which results in the assembly and activation of IRAK4, initiating a signaling cascade that induces cytokine and survival factor expression mediated by the NF-B protein complex. Many B-cell leukemias and lymphomas are associated with constitutive activation of the NF-B protein complex, which contributes to these ca

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CRIS_OUT_19 [2025-04-28 19:01:39 -0400] 1181 Bytes | 282 tokens | Cum: 4066 tkns (50.82% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): ncers' proliferation and survival. The B-cell receptor, or BCR, and TLR pathways drive NF-B activation. Preclinical studies have demonstrated that targeting both the BCR and TLR pathways is more synergistic than targeting either pathway alone. Similarly, preclinical studies targeting IRAKi in combination with FMSlike tyrosine kinase 3, or FLT3, have demonstrated the ability to overcome the adaptive resistance incurred when targeting FLT3 alone. In acute myeloid leukemia, or AML, patient derived xenografts, emavusertib has shown monotherapy anti-tumor activity as well as synergy with both azacitidine and venetoclax. In the clinic, emavusertib has shown anti-tumor activity across a broad range of hematologic malignancies, including monotherapy activity in AML, particularly those with a FLT3 mutation. In non-Hodgkin's lymphoma patients, particularly in primary central nervous system lymphom

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CRIS_OUT_21 [2025-04-28 19:01:39 -0400] 1181 Bytes | 327 tokens | Cum: 4395 tkns (54.94% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): a, or PCNSL, emavusertib has shown anti-tumor activity in combination with a Bruton Tyrosine Kinase, or BTK, inhibitor.

TakeAim Lymphoma

Emavusertib is currently undergoing testing in combination with ibrutinib, a BTK inhibitor, in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, PCNSL (CA-4948-101, NCT03328078), also known as the TakeAim Lymphoma Phase 1/2 study. In June 2022 and December 2023, we provided preliminary clinical data for patients with various hematological malignancies in the combination portion of the ongoing TakeAim Lymphoma Phase 1/2 study. In December 2023, we provided clinical and safety data of emavusertib in combination with ibrutinib in several non-Hodgkin's lymphoma subtypes, including PCNSL patients. In July and December 2024, emavusertib was granted Orphan Drug Designation by the European Commission and the

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CRIS_OUT_23 [2025-04-28 19:01:40 -0400] 1181 Bytes | 287 tokens | Cum: 4684 tkns (58.55% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): U.S. Food and Drug Administration, or FDA, respectively, for the treatment of patients with PCNSL. In September 2024 and March 2025, we provided additional clinical data of emavusertib in combination with ibrutinib in R/R PCNSL. We expect additional data from this study in the fourth quarter of 2025.

In March 2025, we announced that we had completed productive meetings with both the European Committee for Medicinal Products for Human Use, or CHMP, and the FDA on the suitability of using the ongoing TakeAim Lymphoma Phase 1/2 study to support a potential accelerated regulatory path for a Conditional Marketing Authorization, or CMA, submission in Europe and a New Drug Application, or NDA, submission in the U.S.

For submission in Europe, we engaged CHMP for scientific advice on the potential for CMA submission, with the following feedback:

Current, single-arm, study could support a

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CRIS_OUT_25 [2025-04-28 19:01:41 -0400] 790 Bytes | 206 tokens | Cum: 4892 tkns (61.15% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): CMA;

Primary endpoint of Overall Response Rate, or ORR, for a single-arm study is supported;

45 patients may be sufficient to support a CMA, assuming compelling and consistent results;

Due to the rarity of disease the proposed size of the safety database may be acceptable and will be a review issue for CMA; and

Contribution of effect of each of emavusertib and ibrutinib as well as the emavusertib/ibrutinib combination in a BTKi-nave population is required for CMA.

For submission in the...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CRIS_OUT_27 [2025-04-28 19:01:47 -0400] 5859 Bytes | 1573 tokens | Cum: 6467 tkns (80.84% of 8k)
==========================================================================

This is our set of metrics for Curis.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 94,400 | Perf Month: -22.82% | Option/Short: No / Yes | Sales Y/Y TTM: 8.83% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 56.66K | Perf Quarter: -41.32% | Short Float: 2.31% | ROE: -634.71% |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 1.67 | Index: - | Short Ratio: 3.63 | ROI: -195.11% |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 55.55 | Market Cap: 19.46M | Short Interest: 0.21M | Sales Surprise: 51.34% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.19 | Shs Outstand: 10.46M | Beta: 3.69 | EPS Surprise: 6.72% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: 33.00% | Shs Float: 8.92M | Sales Q/Q: 24.07% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: -18.10% | Inst Own: 40.72% | Sales past 5Y: 1.90% | Earnings: Mar 31 BMO |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -53.53% | Insider Own: 14.70% | Employees: 34 | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: 43.08% | Insider Trans: 0.00% | Debt/Eq: - | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading by Curis officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 10259000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -45483000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.86
Average Volume: 109555.35
30-Day High: 2.1
30-Day Low: 1.16

[Detailed Financials: Q3 2024]
- Total Assets: $42,473,000.00
- Total Liabilities: $51,208,000.00
- Total Equity: $-8,735,000.00
- Current Assets: $26,937,000.00
- Current Liabilities: $22,034,000.00

[Income Statement: Q3 2024]
- Revenue: $2,931,000.00
- Net Income: $-10,092,000.00
- Gross Profit: N/A
- Operating Income: $-10,567,000.00
- Earnings Per Share (EPS): -1.7

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $10,858,000.00

[Detailed Financials: Q2 2024]
- Total Assets: $50,413,000.00
- Total Liabilities: $51,107,000.00
- Total Equity: $-694,000.00
- Current Assets: $34,524,000.00
- Current Liabilities: $19,366,000.00

[Income Statement: Q2 2024]
- Revenue: $2,546,000.00
- Net Income: $-11,803,000.00
- Gross Profit: N/A
- Operating Income: $-12,512,000.00
- Earnings Per Share (EPS): -2.03

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-19,960,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Curis (CRIS).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Curis.

2) MARKET_SCORE[]
This conversation was initiated because CRIS is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CRIS.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CRIS could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CRIS to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Curis.

11) ETHICAL_RATING[]
Rate Curis’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Curis.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CRIS_IN_29 [2025-04-28 19:01:47 -0400] 126 Bytes | 29 tokens | Cum: 6710 tkns (83.88% of 8k)
==========================================================================

====================================
[2025-04-28 19:01:47] # Analysis Completed
Elapsed Time: 16.99 seconds